Clinical Trial Results: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brentuximab Vedotin in combination with Lenalidomide for relapsed or refractory T-cell lymphoma including cutaneous presentations; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Anaplastic Large Cell Lymphoma
• Cutaneous T-cell Non-hodgkin Lymphoma
• Lymphomatoid Papulosis

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: John Reneau | Conditions: Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2026-08-13